| Literature DB >> 32582839 |
Jana I Solomun1,2, John D Totten1,3, Thidarat Wongpinyochit1, Alastair J Florence1,3, F Philipp Seib1,3,4.
Abstract
Silk has a long track record of clinical use in the human body, and new formulations, including silk nanoparticles, continue to reveal the promise of this natural biopolymer for healthcare applications. Native silk fibroin can be isolated directly from the silk gland, but generating sufficient material for routine studies is difficult. Consequently, silk fibroin, typically extracted from cocoons, serves as the source for nanoparticle formation. This silk requires extensive processing (e.g., degumming, dissolution, etc.) to yield a hypoallergenic aqueous silk stock, but the impact of processing on nanoparticle production and characteristics is largely unknown. Here, manual and microfluidic-assisted silk nanoparticle manufacturing from 60- and 90-min degummed silk yielded consistent particle sizes (100.9-114.1 nm) with low polydispersity. However, the zeta potential was significantly lower (P < 0.05) for microfluidic-manufactured nanoparticles (-28 to -29 mV) than for manually produced nanoparticles (-39 to -43 mV). Molecular weight analysis showed a nanoparticle composition similar to that of the silk fibroin starting stock. Reducing the molecular weight of silk fibroin reduced the particle size for degumming times ≤30 min, whereas increasing the molecular weight polydispersity improved the nanoparticle homogeneity. Prolonged degumming (>30 min) had no significant effect on particle attributes. Overall, the results showed that silk fibroin processing directly impacts nanoparticle characteristics.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32582839 PMCID: PMC7304816 DOI: 10.1021/acsbiomaterials.0c00202
Source DB: PubMed Journal: ACS Biomater Sci Eng ISSN: 2373-9878
Figure 1Impact of degumming time and manufacturing method on nanoparticle characteristics. (A) Schematic overview of the silk nanoparticle manufacturing process with either the manual or microfluidic setup. Top row: steps for reverse-engineered silk solution. Bottom row: native silk extraction and preparation of stock solution. Red boxes indicate that the process parameters varied. This panel was created with BioRender.com. (B) Qualitative assessment of nanoparticles with SEM (scale bar: 1 μm). (C) Quantitative nanoparticle assessment of size, polydispersity, and surface charge (n ≥ 3).
Figure 2Secondary structure determination of silk nanoparticles. (A) FTIR absorbance spectra in the amide I region of nanoparticles manufactured from 60-min degummed silk with the manual method. Controls include native silk as well as air-dried and autoclaved silk film. The dashed line marks the absorption band between 1622 and 1627 cm–1, which is characteristic of the antiparallel β-sheet structure. (B) Secondary structure content of native silk and silk nanoparticles. Native silk fibroin was obtained from the silk gland with minimal processing. Silk nanoparticles were manufactured either manually or by microfluidics.
Figure 3Analysis of silk fibroin fragmentation and assembly into nanoparticles. SDS-PAGE (right) and densitometry analysis (left) of (A) silk stock solutions prepared from native and degummed B. mori silk and (B) analysis of the silk incorporated into nanoparticles manufactured manually or by microfluidics.
Figure 4In vitro cytotoxicity of silk nanoparticles in macrophages. RAW 264.7 cells were exposed for 48 h to 2.5–250 μg mL–1 nanoparticles prepared from 10-, 30-, 60-, or 90-min degummed silk. Nanoparticles were manufactured using either a (A) manual or (B) microfluidic method. (n = 3).